Interstitial high-dose-rate brachytherapy in eyelid cancer

Mareco, V.; Bujor, L.; Abrunhosa-Branquinho, André; Ferreira, Miguel Reis; Ribeiro, Tiago; Vasconcelos, Ana Luísa; Ferreira, Cidalina Reis; Jorge, Marília

doi:10.1016/j.brachy.2015.03.005

Cited by 15 publications

(39 citation statements)

References 37 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interstitial LDR BT for eyelid carcinomas was reported by several authors and is known to be a good option as definitive treatment for postoperative positive surgical margins or as adjuvant therapy for the early stages of eyelid cancer. However, there are few previous reports of HDR‐ISBT for eyelid carcinomas, and the sample sizes in these reports are small . Azad et al reported eight patients with sebaceous carcinoma of the eyelid treated with radical HDR‐ISBT (39 Gy/6 fr) and a 5‐year local control rate of 57.4% .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

High‐dose‐rate interstitial brachytherapy for a bulky sebaceous carcinoma of the eyelid: A case report

Takagawa

Murakami

Suzuki³

et al. 2019

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Some patients may be treated with radiotherapy if they are unsuitable candidates for surgery or refuse surgical intervention. Previous reports of interstitial low‐dose‐rate (LDR) and high‐dose‐rate (HDR) brachytherapy (BT) for eyelid cancer are few …”

Section: Introductionmentioning

confidence: 99%

High‐dose‐rate interstitial brachytherapy for a bulky sebaceous carcinoma of the eyelid: A case report

Takagawa

Murakami

Suzuki³

et al. 2019

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

“…Recently new techniques to precisely deliver the radiation to the target tumor has been developed that prevent damage to the surrounding healthy tissues and cause minimal radiation toxicities. Currently, interstitial highdose-rate (HDR) brachytherapy and electronic surface brachytherapy (ESB) are the new techniques being used to treat various nonmelanoma skin malignancies including the eyelid carcinomas [10][11][12][13][14][15].…”

Section: Editorialmentioning

confidence: 99%

“…Local recurrence rate was less with this technique. It caused madarosis in 65% of cases only among those who received high prescribed volumes [10]. Another study utilizing interstitial HDR brachytherapy with Ir-192 wires (with linear activity of 1.2-1.7 mCi/cm) at a dose of 66 Gy (range 51-70) for the eyelid tumors resulted in local tumor control in 97% and provided good functional & cosmetic outcomes in 68%.…”

mentioning

confidence: 99%

“…Specialized equipment is required to protect the eye from radiation with this technique. Plaque RT also caused marked ophthalmic complications such as cataract, radiation retinopathy and rubeosis iridis.Interstitial HDR brachytherapy with Iridium (Ir)-192 is an alternative modality to treat small eyelid tumors, incompletely excised primary tumors, or recurrent tumors after prior RT [10][11][12]. Interstitial HDR brachytherapy using Ir-192 wires at a dose of 42.75 Gy (range 32-50) with 10 fractions (range 9-11) twice a day (6 h apart) controlled the local eyelid tumors by 94% and had good cosmetic effect in 70%.…”

mentioning

confidence: 99%

See 1 more Smart Citation

What is New in the Treatment of Eyelid Tumors with Radiation Therapy?

Turaka¹,

Turaka²,

Koneru³

2016

OMICS J Radiol

View full text Add to dashboard Cite

EditorialMalignant tumors of the eyelids can cause considerable functional and aesthetic complications. Most common eyelid tumor is basal cell carcinoma (BCC) followed by squamous cell carcinoma, sebaceous gland carcinoma, Merkel cell carcinoma and malignant melanoma (rare) [1]. They can be located at lower eyelid (most common site) or upper eyelid, outer canthus and inner canthus. Surgical excision is the standard primary treatment option for the eyelid tumors. However, in cases with incompletely excised primary tumors, recurrent tumors, or inoperable large primary tumors and elderly patients who cannot tolerate general anesthesia with significant co-morbidities, radiation therapy (RT) is considered as an effective alternative/adjuvant treatment modality [2][3][4][5][6][7]. Different radiation therapeutic methods such as external beam radiotherapy (EBRT) with x-rays [superficial (45-100 Kv), orthovoltage (100-250 Kv)] or megavoltage photons & electrons and radionuclide plaque brachytherapy has been used to treat various eyelid tumors with good success [2][3][4][5][6][7][8][9]. However, acute and chronic radiation side-effects (skin reactions, eyelid telangiectasia, eyelid atrophy, eyelash loss (madarosis), epiphora (tearing), ocular surface disorders (dry eyes), cataract, radiation papillopathy, retinopathy & maculopathy and second malignant neoplasms) can lead to significant functional and visual disabilities. Recently new techniques to precisely deliver the radiation to the target tumor has been developed that prevent damage to the surrounding healthy tissues and cause minimal radiation toxicities. Currently, interstitial highdose-rate (HDR) brachytherapy and electronic surface brachytherapy (ESB) are the new techniques being used to treat various nonmelanoma skin malignancies including the eyelid carcinomas [10][11][12][13][14][15].Contact X-ray radiotherapy (50 kV) was used in the past to treat the small (<2 cm) eyelid tumors. At a dose of 42 Gray (Gy)/7 fractions/ 4 weeks, there was excellent regression of the tumors with long-term tumor control in 98%. However, loss of eye lashes, punctal stenosis, skin depigmentation was noticed even at doses of 1 or 2 fractions of 6 Gy per week. Also local tumor relapse was seen in few cases around the irradiated area. The cosmetic results were good with x-ray RT [2]. Following orthovoltage radiotherapy of medial canthal BCC, 10-year tumor control rate was 94% with no recurrence rates. However, patients developed significant complications within the radiation field such as madarosis, epiphora, ocular surface disorders and conjunctival scarring [3]. When eyelid tumors (1-4 cm size) were treated by electron beam therapy at a dose of 45-70 Gy in daily fractions of 2-4 Gy, though there was reasonable local tumor regression, few cases had recurrences (11%) and few had local radiation side effects such as skin atrophy and mild deformities [4].EBRT can be considered another option for treating the eyelid tumors [5][6][7]. Primary eyelid tumors when treated with median radiatio...

show abstract